TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34757134
Drug: Probiotic formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formula (Lactobacillus acidophilus LA‐5, Lactobacillus plantarum, Bifidobacterium lactis BB‐12, Saccharomyces boulardii) administered as two sachets twice daily for 15 days
Study: 33050928
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg administered subcutaneously every 4 weeks
Study: 33743799
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (1 unit, 200-399 mL)
Study: 35900726
Drug: Talazoparib, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib, 1 mg orally daily and avelumab, 10 mg/kg intravenously every 2 weeks
Study: 38942209
Drug: Cariprazine 3-12
Normalized name: cariprazine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 3-12 mg/d
Study: 34418399
Drug: Non-immunogenic staphylokinase
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-immunogenic staphylokinase (10 mg)
Study: 34418399
Drug: Alteplase (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (0.9 mg/kg, maximum 90 mg)
Study: 33141078
Drug: Aquatic exercises
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercises (16 weeks, twice per week, 45 min/session)
Study: 33952398
Drug: SDS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDS group (subcutaneous sufentanil and dexmedetomidine)
Study: 33952398
Drug: SDI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDI group (intravenous sufentanil and dexmedetomidine)
Study: 33952398
Drug: SS group
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS group (subcutaneous sufentanil)
Study: 33952398
Drug: SI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SI group (intravenous sufentanil)
Study: 35799113
Drug: Potentially Inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially Inappropriate Medications (PIMs)
Study: 33452350
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) (propofol/remifentanil)
Study: 34910219
Drug: Second 1-g
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second 1-g TXA
Study: 36059420
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of apatinib
Study: 32542334
Drug: Novel botanical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel botanical formula (6 mg, 10 mg, or 14 mg of lutein)
Study: 32542334
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein formula
Study: 32542334
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg lutein formula
Study: 32542334
Drug: Novel botanical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel botanical formula (all doses)
Study: 36217243
Drug: Systemic congruence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic congruence couple therapy (CCT)
Study: 36217243
Drug: Individual-based treatment-as-usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-based treatment-as-usual (TAU)
Study: 34780099
Drug: CAMS‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMS‐G
Study: 36252151
Drug: Formula C
Normalized name: Stress Formula Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula C (cannabidiol-rich preparation)
Study: 35428274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (education about clinical manifestations, risk factors, diagnosis, treatment, and nursing care for knee via printed materials)
Study: 32359094
Drug: Low skeletal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low skeletal muscle index (myopenia), high intramuscular adipose tissue content (myosteatosis), and high visceral to subcutaneous adipose tissue area (adiposity)
Study: 32284380
Drug: Durlobactam (DUR)
Normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durlobactam (DUR) 1 g
Study: 32284380
Drug: Durlobactam (DUR)
Normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durlobactam (DUR) 0.25 to 8 g (single ascending doses)
Study: 32284380
Drug: Durlobactam (DUR)
Normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durlobactam (DUR) 0.25 to 2 g (multiple ascending doses every 6 hours for 29 doses)
Study: 32284380
Drug: Durlobactam (DUR)
Normalized name: Durlobactam
DrugBank: Durlobactam (DB16704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durlobactam (DUR) 1 g with SUL (1 g) and/or IMI-CIL (0.5/0.5 g)
Study: 35066737
Drug: Carvedilol-IR twice
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol-IR twice a day
Study: 32503608
Drug: YinQiSanHuang-antiviral decoction
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: YinQiSanHuang-antiviral decoction with entecavir
Study: 34295663
Drug: Docetaxel (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (37.5 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (DC group)
Study: 34295663
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (GC group)
Study: 34295663
Drug: Previous literature
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous literature anti-tumor therapy only group
Study: 32325794
Drug: Lactobacilli (L.)
Normalized name: lactobacillic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli (L.) rhamnosus GR‐1 and L. reuteri RC‐14, 5 × 10^9 CFU, 2 capsules/day for 2 months
Study: 32325794
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (both groups)
Study: 33376176
Drug: Adjunct oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct oral betamethasone for 2 days
Study: 32019557
Drug: Fluid restriction
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid restriction + low CVP (Group L)
Study: 32220375
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of pre-operative bowel preparation
Study: 35792365
Drug: Liraglutide 1.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.80 mg
Study: 32003275
Drug: Medication Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Adherence and Care Engagement (MACE)
Study: 33813569
Drug: Sugammadex 1
Normalized name: sugammadex 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 1 mg/kg
Study: 35750637
Drug: AdVEGF‐D gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdVEGF‐D gene therapy
Study: 32681063
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (recorded maternal singing/heartbeat)
Study: 34405233
Drug: Early-onset stage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-onset stage III colon adenocarcinoma (EO-CC)
Study: 35618953
Drug: Reparixin 1200
Normalized name: Réparixine
DrugBank: Reparixin (DB12614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparixin 1200 mg orally three times daily for up to 21 days
Study: 33621540
Drug: NT-proBNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP plasma concentrations ≤400 pg/mL
Study: 33621540
Drug: NT-proBNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP plasma concentrations 400-999 pg/mL
Study: 33621540
Drug: NT-proBNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP plasma concentrations 1000-1999 pg/mL
Study: 33621540
Drug: NT-proBNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP plasma concentrations 2000-2999 pg/mL
Study: 33621540
Drug: NT-proBNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP plasma concentrations ≥3000 pg/mL
Study: 33048053
Drug: Occlusal splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal splint therapy (Control)
Study: 35352280
Drug: Erlotinib 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 75 mg QD plus ritonavir 200 mg QD
Study: 35352280
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg QD (control arm)
Study: 32423463
Drug: Interprofessional collaboration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional collaboration concept involving GPs in regional teams with on-call schedules, pre-weekend visits, joint meetings, documentation, and improved medication safety.
Study: 32423463
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receives treatment as usual.
Study: 36157118
Drug: Anti-bacterial antibody
Normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-bacterial antibody responses in CD patients
Study: 36157118
Drug: Anti-bacterial antibody
Normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-bacterial antibody responses in healthy controls
Study: 34437752
Drug: REGN1908-1909 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1908-1909 (600 mg)
Study: 34437752
Drug: REGN1908-1909 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1908-1909 (150 mg)
Study: 34437752
Drug: REGN1908-1909 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1908-1909 (300 mg)
Study: 36272526
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) with cisplatin+vinorelbine
Study: 34327047
Drug: First-line therapies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line therapies for POTS
Study: 34327047
Drug: Second-line therapies
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapies for POTS
Study: 34327047
Drug: Third-line therapies
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-line therapies for POTS
Study: 32993879
Drug: Ultra‐lose dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra‐lose dose imaging protocol (ULDP)
Study: 32993879
Drug: Standard low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard low‐dose imaging protocol (LDP)
Study: 32329435
Drug: Zolpidem extended-release
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem extended-release
Study: 35218300
Drug: Immediate antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiretroviral therapy (ART) offered through trial clinics
Study: 33221932
Drug: MDMA-assisted psychotherapy
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted psychotherapy (75–125 mg) in non-taper group
Study: 33221932
Drug: MDMA-assisted psychotherapy
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted psychotherapy (75–125 mg) in taper group
Study: 33221932
Drug: MDMA-assisted psychotherapy
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA-assisted psychotherapy (75–125 mg)
Study: 35726101
Drug: Ultrasound-guided injections
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injections (group 2)
Study: 35726101
Drug: Blind injections
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind injections (group 1)
Study: 33726499
Drug: pUDK‐HGF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: pUDK‐HGF treatment (intramuscular injection on days 0, 14, and 28)
Study: 33726499
Drug: pUDK‐HGF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: pUDK‐HGF treatment
Study: 36069821
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (taxane and anthracycline-based) with investigational agents
Study: 36069821
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (taxane and anthracycline-based) without investigational agents
Study: 33982806
Drug: IFN-α-2b aerosol
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α-2b aerosol inhalation (5,000,000 U twice daily)
Study: 33982806
Drug: IFN-α-2b therapy
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α-2b therapy
Study: 33982806
Drug: IFN-α-2b treatment
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α-2b treatment 0–2 days after symptom onset
Study: 33982806
Drug: IFN-α-2b treatment
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α-2b treatment 3–5 days after symptom onset
Study: 33982806
Drug: IFN-α-2b treatment
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α-2b treatment 6–8 days after symptom onset
Study: 33091354
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion (whole blood at a target volume of 20 mL per kg)
Study: 32740950
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed guar gum (PHGG) 10 g twice daily for 14 days prior and 14 days during pelvic radiation
Study: 34937821
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin (HH) receiving an initial heparin dose of 450 u/kg
Study: 34937821
Drug: Heparin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin concentration monitoring (HC) with Hepcon HMS
Study: 34937821
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving a standard heparin dose of 300 u/kg
Study: 36239038
Drug: Zavegepant 10
Normalized name: zavegepant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zavegepant 10 mg
Study: 36239038
Drug: Zavegepant 20
Normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zavegepant 20 mg
Study: 36239038
Drug: Zavegepant 5
Normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zavegepant 5 mg
Study: 36599584
Drug: 1-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month DAPT followed by clopidogrel monotherapy
Study: 32684537
Drug: 3-month DAPT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month DAPT followed by aspirin monotherapy
Study: 32843081
Drug: Dutogliptin plus
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutogliptin plus filgrastim (G-CSF)
Study: 33183672
Drug: F(ab')2 antivenom
Normalized name: Crotalidae immune F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: F(ab')2 antivenom therapy plus local cryotherapy
Study: 33183672
Drug: F(ab')2 antivenom
Normalized name: Crotalidae immune F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: F(ab')2 antivenom therapy
Study: 35652703
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment + escitalopram
Study: 35652703
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment + pramipexole
Study: 35652703
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment + transcranial magnetic stimulation (TMS)
Study: 32871701
Drug: Family‐Focused Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐Focused Treatment for Childhood Depression (FFT‐CD)
Study: 33726804
Drug: Enzalutamide (Xtandi®)
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide (Xtandi®) 160 mg (4x40 mg) daily for five consecutive days
Study: 33726804
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care treatment for patients hospitalised with COVID‐19
Study: 32875505
Drug: Integrated clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated clinical prediction rule (iCPR) system for antibiotic prescribing in ARIs
Study: 33664429
Drug: MK-7 375
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 375 µg daily
Study: 32049562
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (30 maximum inspirations at 50% PImax, twice per day, 6 days per week)
Study: 35357564
Drug: OFF medication
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFF medication (PD patients)
Study: 32717926
Drug: Ethanol consumption
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol consumption (35 g daily for eight weeks)
Study: 33687323
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBTi) and manual standardized stress acupuncture (MSSA)
Study: 33687323
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBTi) only
Study: 32471328
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not using oral contraceptives)
Study: 36216658
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 or 200 mg daily plus best supportive care (BSC)
Study: 34096641
Drug: Parent-led cognitive
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-led cognitive behavioural therapy (From Timid to Tiger), 8 sessions
Study: 36256505
Drug: CC-90001 (10–720
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90001 (10–720 mg single dose or 30–480 mg once daily for 7–18 days)
Study: 36256505
Drug: CC-90001
Normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90001
Study: 33971928
Drug: Music exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music exercise therapy
Study: 33971928
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation therapies
Study: 35962638
Drug: 3 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg/kg of intranasal desmopressin acetate
Study: 35962638
Drug: 1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL/kg of intranasal sodium chloride 0.65% (placebo)
Study: 33065164
Drug: Prognostic model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic model for predicting deterioration in health-related quality of life (dHRQoL) based on 12/87 selected variables related to chronic conditions, medication, functional status, well-being, and HRQoL.
Study: 32817632
Drug: 12% N,N‐diethylbenzamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% N,N‐diethylbenzamide w/w cream distributed by village health volunteers (VHVs)
Study: 37340514
Drug: Intralesional autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional autologous PRP plus classic topical treatment
Study: 37340514
Drug: Topical compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical compounds only
Study: 33511686
Drug: Tocilizumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (single infusion)
Study: 36117310
Drug: Systemic inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic inflammation (SI) with LPS injections (1 ng/kg and 0.5 ng/kg)
Study: 33534818
Drug: Combined protocol
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined protocol using an optimised MUAC-based dose of ready-to-use therapeutic food (RUTF)
Study: 33422245
Drug: Bio‐Manguinhos‐Fiocruz standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Manguinhos‐Fiocruz standard dose
Study: 33422245
Drug: Bio‐Manguinhos‐Fiocruz fractional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Manguinhos‐Fiocruz fractional dose
Study: 33422245
Drug: Chumakov Institute
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chumakov Institute of Poliomyelitis and Viral Encephalitides standard dose
Study: 33422245
Drug: Chumakov Institute
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chumakov Institute of Poliomyelitis and Viral Encephalitides fractional dose
Study: 33422245
Drug: Institut Pasteur
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institut Pasteur Dakar standard dose
Study: 33422245
Drug: Institut Pasteur
Normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institut Pasteur Dakar fractional dose